Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: BPaL

Displaying 18 papers

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

Author(s): Denise Evans, Kamban Hirasen, Clive Ramushu, Lawrence Long, Edina Sinanovic, Francesca Conradie, Pauline Howell, Xavier Padanilam, Hannetjie Ferreira, Ebrahim Variaiva, Shakira Rajaram, Aastha Gupta, Sandeep Juneja, Norbert Ndjeka

10/2024

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Drug Market, TB Market

Savings from the introduction of BPaL and BPaLM regimens at the country level

Publication: IJTLD Open

Author(s): C. Auer, A. Gupta, C. Malbacius, A. Ghafoor, Y. Kock, O. Medvedieva, P. Hanlon, P. Steinmann, and S. Juneja

8/2024

Tags: BPaL, MDR-TB, TB Drug Market, TB Market

Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan

Publication: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Author(s): B. Myrzaliev, M. Ahmatov, A. Duishekeeva, A. Kulzhabaeva, A. Kadyrov, A. Toktogonova, G. Abdulaeva, D.F. Wares , V. Mirtskhulava, M. Mbenga, A. Slyzkyi, S. Foraida, M. Diachenko, S. Juneja, G. Turdumambetova, A. Musaeva, A. Gebha

7/2024

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Regimen Change, XDR-TB

Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines

Publication: The International Journal of Tuberculosis and Lung Disease

Author(s): D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja

6/2024

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, Regimen Change, TB Drug Market

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

Publication: PLOS One

Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu

1/2024

Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

Publication: PLOS Global Public Health

Author(s): Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

Publication: Clinical Infectious Diseases

Author(s): Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta, Linh Nguyen, Samuel Schumacher, Tim Schlub, Greg Fox

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

Publication: Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

3/2023

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

Publication: PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

11/2022

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Publication: New England Journal of Medicine

Author(s): Francesca Conradie, et al., for the ZeNix Trial Team

9/2022

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, XDR-TB

Budgetary impact of using BPaL for treating extensively drug resistant tuberculosis

Publication: BMJ Global Health

Author(s): Christiaan Mulder, Stephan Rupert, Ery Setiawan, Elmira Mambetova, Patience Edo, Jhon Sugiharto, Sani Useni, Shelly Malhotra, Sarah Cook-Scalise, Imran Pambudi, Abdullaat Kadyrov, Adebola Lawanson, Susan van den Hof, et al

1/2022

Tags: BPaL, MDR-TB, TB Market, XDR-TB

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Publication: BMC Public Health

Author(s): S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra et al

7/2021

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, TB Drug Market, TB Market, XDR-TB

The Clinical Dose of Pretomanid: An Exposure-Response Perspective

Author(s): Jerry R. Nedelman, David H. Salinger, Vishak Subramoney, Rob Woolson, Karen Wade, Mengchun Li, Daniel Everitt, Carl M. Mendel, Mel Spigelman

12/2020

Tags: BPaL, Clinical Development, Nix-TB, Pretomanid/PA-824

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Publication: The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

3/2020

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB